Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: November 13, 2019)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Genetics/Family History

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit every 2 weeks, plus radiation

PHASE: I

NCT ID: NCT03524170

Immunotherapy and Radiation Therapy for ER+ HER2- Metastatic Breast Cancer

RACHEL1: A Phase I Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Scientific Title

Purpose
To determine the best dose, safety and effects (good and bad) of M7824 combined with radiation therapy.
Who is this for?
Women and men with estrogen receptor positive and HER2 negative metastatic (stage IV) breast cancer. You must have at least two sites of metastatic disease by imaging.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">M7824, by IV, every 2 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Radiation therapy, 5 or 10 sessions</li> <li class="seamTextUnorderedListItem">Biopsy after 2 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">M7824 (MSB0011359C) is a protein with two components: PD-L1 antibody and TGF-β receptor. </li> <li class="seamTextUnorderedListItem">M7824 is currently being used for research purposes only.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03524170' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://stm.sciencemag.org/content/10/424/eaan5488' target='_blank'>Science Translational Medicine: M7824</a> </li></ul>
See more